Connect with us

Brexit

#Coreper approves #EMA and #EBA relocations

SHARE:

Published

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

On 17 October, the Permanent Representatives Committee (Coreper) approved, on behalf of the Council, an agreement with the European Parliament on the text of the regulations for the relocation of the European Medicines Agency (EMA) to Amsterdam, and of the European Banking Authority (EBA) to Paris, writes Martin Banks. 

The two agencies are currently based in London, in the UK, and need to be relocated in the context of the UK's withdrawal from the EU (Brexit).  The European Medicines Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines. It is therefore essential for the functioning of the single market for medicines in the EU.

The European Banking Authority works to ensure effective and consistent prudential regulation and supervision across the European banking sector. Among other tasks, the EBA assesses risks and vulnerabilities in the EU banking sector through regular risk assessment reports and EU-wide stress tests.

Share this article:

Share this:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.

Trending